- Home
- KOYN vs CABA Comparison
KOYN vs CABA Comparison
Compare KOYN & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOYN | CABA |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.5M | 339.1M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KOYN | CABA |
|---|---|---|
| Price | $10.29 | $1.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | 81.4K | ★ 4.9M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.92 | $1.18 |
| 52 Week High | $10.30 | $4.23 |
Technical Indicators
Market Signals| Indicator | KOYN | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 72.23 | 41.97 |
| Support Level | $10.08 | N/A |
| Resistance Level | N/A | $1.63 |
| Average True Range (ATR) | 0.01 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 100.00 | 63.33 |
Price Performance
Historical ComparisonAbout KOYN CSLM Digital Asset Acquisition Corp III Class A Ordinary Shares
CSLM Digital Asset Acquisition Corp III Ltd is a blank check company that acts to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.